https://www.bioworld.com/rss en-us These graphs compare the performance of the biotech stocks for all of 2026 using the BioWorld Stock Indicator and the Nasdaq Biotech Index. http://www.bioworld.com/articles/732800 Fri, 17 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732800-bioworld-and-nasdaq-stock-indices Year-to-date money raised in public, private and other financings of biopharma companies. http://www.bioworld.com/articles/732798 Fri, 17 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732798-biopharma-money-raised-jan-1-july-16-2026 Total raised in public, private and other financings of biopharma companies, comparing 2019-2026. http://www.bioworld.com/articles/732797 Fri, 17 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732797-money-raised-by-biopharma Biopharma money raised to-date and by month in 2026, including public, private and other financings. http://www.bioworld.com/articles/732799 Fri, 17 Jul 2026 12:25:00 -0400 https://www.bioworld.com/articles/732799-biopharma-money-raised-by-month-in-2026-usm Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion. BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.]]> http://www.bioworld.com/articles/732723 Fri, 17 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732723-junes-257b-m-and-a-haul-caps-biopharmas-record-breaking-first-half Chess board and pieces, blocks spelling out M&A Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization. http://www.bioworld.com/articles/732692 Thu, 16 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732692-capital-remains-selective-in-barbell-biotech-market International currency symbols Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition. http://www.bioworld.com/articles/732598 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732598-asia-deal-flurry-draws-az-spero-to-1b-dizal-innovent-assets Global deals illustration The top 10 biopharma stock gainers and losers for the week. http://www.bioworld.com/articles/732589 Mon, 13 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732589-biggest-gainers-and-losers-for-july-6-10-2026 Year-to-date money raised in public, private and other financings of biopharma companies. http://www.bioworld.com/articles/732623 Fri, 10 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732623-biopharma-money-raised-jan-1-july-9-2026 Total raised in public, private and other financings of biopharma companies, comparing 2019-2026. http://www.bioworld.com/articles/732622 Fri, 10 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732622-money-raised-by-biopharma Med-tech M&As through the first half (H1) of 2026 reached $75.73 billion in collective value, the highest H1 total since 2022’s $120.4 billion and well above every other year in BioWorld’s records. June contributed $12.21 billion, a rebound from May’s relatively quiet $1.51 billion. BioWorld’s records. June contributed $12.21 billion, a rebound from May’s relatively quiet $1.51 billion. ]]> http://www.bioworld.com/articles/732530 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732530-danaher-masimo-close-caps-med-techs-strongest-first-half-since-2022 M&A letters over missing puzzle pieces The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the topics for debate in the aftermath of the phase III fizzle with gene silencer Wainua (eplontersen), advanced by Astrazeneca plc and Ionis Pharmaceuticals Inc. http://www.bioworld.com/articles/732529 Fri, 10 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732529-combination-locked-out-in-attr-cm-dead-expert-says Human heart within crosshairs Of all the U.S. SEC’s recent proposed rules to make going, and staying, public more attractive, perhaps the most beneficial for biopharma and med-tech startups is the amendment that would give public companies the flexibility to file semi-annual rather than quarterly reports, Ben Bradford, head of external affairs at Massbio, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/732433 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732433-sec-reform-good-for-life-sciences-startups-but-getting-pushback Gears with regulatory words To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732471 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732471-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732470 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732470-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork The April 2024 full U.S. FDA approval of Pfizer Inc. and Genmab A/S’ tissue factor-targeting antibody-drug conjugate Tivdak (tisotumab vedotin) for cervical cancer sparked interest from drug developers in the strategy, which has been known about for a while. http://www.bioworld.com/articles/732286 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732286-post-tivdak-research-in-tissue-factor-multiplies Tivdak Credit: Business Wire The top 10 biopharma stock gainers and losers for the week. http://www.bioworld.com/articles/732295 Mon, 06 Jul 2026 11:00:00 -0400 https://www.bioworld.com/articles/732295-biggest-gainers-and-losers-for-june-29-july-3-2026 To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732415 Fri, 03 Jul 2026 09:00:20 -0400 https://www.bioworld.com/articles/732415-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe Year-to-date money raised in public, private and other financings of biopharma companies. http://www.bioworld.com/articles/732414 Thu, 02 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732414-biopharma-money-raised-jan-1-july-2-2026 Total raised in public, private and other financings of biopharma companies, comparing 2019-2026. http://www.bioworld.com/articles/732413 Thu, 02 Jul 2026 13:00:00 -0400 https://www.bioworld.com/articles/732413-money-raised-by-biopharma Biopharma financings across all categories totaled $59.76 billion on 567 deals in the first half (H1) of 2026, more than double H1 2025’s $29.53 billion across 501 transactions. http://www.bioworld.com/articles/732277 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732277-h1-2026-biopharma-financings-double-from-last-year-approach-pandemic-highs Blocks with upward arrows To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.” BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”]]> http://www.bioworld.com/articles/732273 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732273-behind-chinas-retractions-a-paper-mill-economy-built-on-incentives China in red on globe With more and more approved products, cell and gene therapies (CGTs) are moving from the initial stronghold in academic medical centers, and these complex biologics are now available across a wider network of treatment centers. http://www.bioworld.com/articles/732272 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732272-cell-and-gene-therapy-access-is-up-but-capacity-constraints-may-be-looming Stem cells and DNA As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732394 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732394-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion. The figure reflects a sector that is holding well above the low years of 2022 and 2023. http://www.bioworld.com/articles/732392 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732392-follow-ons-lead-a-mixed-first-half-of-2026-for-med-tech-financing Global currency Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of those deals topping $7.5 billion, up 23% from the year-ago semester and just slightly below H1 2024, which saw a total of $7.84 billion in large financings. http://www.bioworld.com/articles/732260 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732260-large-vc-financings-improve-in-h1-2026 Rebound arrows As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. http://www.bioworld.com/articles/732258 Wed, 01 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732258-china-trial-retractions-put-data-transparency-in-spotlight Magnifying glass atop paperwork Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model moves closer to adoption in real-world clinical and military practice, technological advances are sparking concerns over public health, ethics and national security. http://www.bioworld.com/articles/732225 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732225-ascending-bci-systems-deepen-national-security-ethical-concerns Brain made of chip and circuits The top 10 biopharma stock gainers and losers for the week. http://www.bioworld.com/articles/732234 Mon, 29 Jun 2026 11:00:00 -0400 https://www.bioworld.com/articles/732234-biggest-gainers-and-losers-for-june-22-26-2026 Year-to-date money raised in public, private and other financings of biopharma companies. http://www.bioworld.com/articles/732224 Fri, 26 Jun 2026 13:00:00 -0400 https://www.bioworld.com/articles/732224-biopharma-money-raised-jan-1-june-25-2026